Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(146 produtos)
- Bcr-Abl(102 produtos)
- EGFR(572 produtos)
- FAK(72 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(245 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(79 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(268 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1431 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Apoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Fórmula:C23H21ClN8O2S2Cor e Forma:SolidPeso molecular:541.048Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SCor e Forma:SolidPeso molecular:532.63JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401DD0-2363
<p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>Fórmula:C36H36ClFN6O4Cor e Forma:SolidPeso molecular:671.16PTD10
CAS:<p>PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.</p>Fórmula:C49H51N11O8Pureza:98%Cor e Forma:SolidPeso molecular:922EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Fórmula:C68H84N12O9Pureza:98%Cor e Forma:SolidPeso molecular:1213.47Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Fórmula:C33H34N4O3Cor e Forma:SolidPeso molecular:534.648KIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Fórmula:C26H18F3N5O2Cor e Forma:SolidPeso molecular:489.449HIF-1 inhibitor-4
CAS:<p>HIF-1 inhibitor-4 (HIF-1 inhibitor-4) is a HIF-1 inhibitor with IC50 of 560 nM.</p>Fórmula:C18H19IN2O2Pureza:99.26%Cor e Forma:SolidPeso molecular:422.26INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Fórmula:C30H38N4O3Pureza:98.93%Cor e Forma:SolidPeso molecular:502.65HIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Cor e Forma:Odour SolidMY-1576
<p>MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.</p>Fórmula:C25H29ClN8O2Cor e Forma:SolidPeso molecular:509VEGFR-2-IN-36
<p>VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstrated</p>Fórmula:C24H23N7O5Pureza:98%Cor e Forma:SolidPeso molecular:489.48cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Fórmula:C28H28N2O3Cor e Forma:SolidPeso molecular:440.53EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Fórmula:C27H31N3O2Cor e Forma:SolidPeso molecular:429.24163PROTAC EGFR degrader 4
CAS:<p>PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).</p>Fórmula:C55H70N12O4SCor e Forma:SolidPeso molecular:995.29Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidLyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Cor e Forma:SolidPeso molecular:915.028Sorafenib-d4
CAS:<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Fórmula:C21H16ClF3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:468.85AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Fórmula:C58H70F3N9O9Pureza:98%Cor e Forma:SolidPeso molecular:1094.23PF15 TFA
<p>PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.</p>Fórmula:C46H50F3N13O8Pureza:98%Cor e Forma:SolidPeso molecular:969.97VEGFR-2-IN-64
<p>VEGFR-2-IN-64 (Compound 28) is an inhibitor of VEGFR2 with an IC50 of 27.8 nM. It suppresses the proliferation of cancer cells A549, T-47D, and Caco-2, exhibits anti-migration and anti-colony formation activities in T-47D cells, and induces apoptosis in T-47D cells.</p>Fórmula:C72H123N9O6Cor e Forma:SolidPeso molecular:1210.8PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Fórmula:C17H12F3N3O2Cor e Forma:SoildPeso molecular:347.29PROTAC FLT-3 degrader 1
CAS:<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Fórmula:C52H61N9O9S2Pureza:98%Cor e Forma:SolidPeso molecular:1020.23VEGFR/PARP-IN-1
<p>VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.</p>Fórmula:C29H27N9OPureza:98%Cor e Forma:SolidPeso molecular:517.58Si5-N14
CAS:<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Fórmula:C78H160N6O5Si2Cor e Forma:SolidPeso molecular:1318.31AKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Fórmula:C17H14N6Pureza:99.88%Cor e Forma:SolidPeso molecular:302.33DSPE-PEG2000-A7R
<p>DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.</p>Cor e Forma:Odour SolidMersalyl
CAS:<p>Mersalyl is an organic mercurial diuretic.</p>Fórmula:C13H16HgNNaO6Cor e Forma:SolidPeso molecular:505.854DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidAXL/Angiokinase-IN-1
<p>AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.</p>Fórmula:C31H34ClN5O2Cor e Forma:SolidPeso molecular:544.09AMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Fórmula:C29H39ClN7O2PCor e Forma:SolidPeso molecular:584.1PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.44RR-src
CAS:<p>Tyrosine kinase substrate peptide</p>Fórmula:C64H106N22O21Pureza:98%Cor e Forma:Lyophilized PowderPeso molecular:1519.66Multi-kinase-IN-4
<p>Multi-kinase-IN-4 (compound 5d) is a multi-targeted kinase inhibitor active against VEGFR2, EGFR, HER2, and CDK2, with respective IC50 values of 0.33, 0.22, 0.</p>Fórmula:C21H20ClFN2OSPureza:98%Cor e Forma:SolidPeso molecular:402.91SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Fórmula:C67H82F3N11O9SPureza:98%Cor e Forma:SolidPeso molecular:1274.5SI-2
CAS:<p>SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.</p>Fórmula:C15H15N5Pureza:98.4%Cor e Forma:SolidPeso molecular:265.31DB1113
CAS:<p>DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.</p>Fórmula:C59H68F3N13O6SCor e Forma:SolidPeso molecular:1144.31Wu-5
CAS:<p>Wu-5 is a potent USP10 inhibitor that inhibits FLT3 and AMPK pathways, promoting the breakdown of FLT3-ITD and inducing apoptosis.</p>Fórmula:C15H13NO7SPureza:99.29%Cor e Forma:SoildPeso molecular:351.33PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Fórmula:C43H40N10O6Pureza:98%Cor e Forma:SolidPeso molecular:792.84FLT3/VEGFR2-IN-1
<p>FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.</p>Fórmula:C29H35N7O5Cor e Forma:SolidPeso molecular:561.63(R)-3-Hydroxy Midostaurin
CAS:<p>(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.</p>Fórmula:C35H30N4O5Pureza:98%Cor e Forma:SolidPeso molecular:586.648Lyn peptide inhibitor
CAS:<p>Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.</p>Fórmula:C115H184N30O24Pureza:98%Cor e Forma:SolidPeso molecular:2370.91MHES0488A
<p>MHES0488A is a selective humanized antibody targeting HER2, with a KD value of 0.8 nM. It constitutes the antibody portion of DHES0815A. Upon cellular internalization, MHES0488A is transported to lysosomes, releasing PBD-monoamide into the nucleus, where it alkylates DNA, inducing DNA damage and apoptosis. It shows potential for research in cancers such as HER2-positive breast cancer and gastric cancer.</p>Cor e Forma:Odour LiquidTrastuzumab emtansine
CAS:<p>Trastuzumab emtansine is a HER2-targeted ADC for advanced breast cancer, combining trastuzumab with DM1 cytotoxicity.</p>Pureza:98%Cor e Forma:LiquidSNIPER(ABL)-058
CAS:<p>SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein</p>Fórmula:C62H75N11O9SPureza:98%Cor e Forma:SolidPeso molecular:1150.39BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Fórmula:C27H29Cl2FN8O3Pureza:99.11%Cor e Forma:Odour SolidPeso molecular:603.47FAK-IN-24
CAS:<p>FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.</p>Fórmula:C39H45Cl2F3N8O3Cor e Forma:SolidPeso molecular:801.728SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Fórmula:C19H15N5O2SCor e Forma:SolidPeso molecular:377.42DSPE-PEG5000-A7R
<p>DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Cor e Forma:Odour SolidIbrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Fórmula:C56H80N12O9SPureza:98%Cor e Forma:SolidPeso molecular:1097.39TLT8
<p>TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.</p>Cor e Forma:Odour SolidEGFR-TK-IN-5
<p>EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.</p>Fórmula:C26H20ClFN4OSCor e Forma:SolidPeso molecular:490.98MP-RM-1
<p>MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.</p>Cor e Forma:Odour LiquidHER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11ALK-IN-9
CAS:<p>ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.</p>Fórmula:C20H21FN6O3Cor e Forma:SolidPeso molecular:412.425FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Fórmula:C36H42N12O6Cor e Forma:SolidPeso molecular:738.33503DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidDuligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidBV02
CAS:<p>BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.</p>Fórmula:C20H15N3O5Pureza:99.82%Cor e Forma:SolidPeso molecular:377.35ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Fórmula:C47H53BrCl2N10O7SPureza:98%Cor e Forma:SolidPeso molecular:1052.86Coumermycin A1
CAS:<p>Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.</p>Fórmula:C55H59N5O20Cor e Forma:SolidPeso molecular:1110.092DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Fórmula:C55H62N10O8Cor e Forma:SolidPeso molecular:991.163LC-SF-14
<p>LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.</p>Fórmula:C44H50Cl3N13O5SCor e Forma:SolidPeso molecular:977.28442IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Fórmula:C20H19N3O5Pureza:97.64% - 99.31%Cor e Forma:SolidPeso molecular:381.39EGFR-IN-151
<p>EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.</p>Cor e Forma:Odour SolidCetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Cor e Forma:Odour LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Cor e Forma:SolidPeso molecular:907.03MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47SIAIS178
CAS:<p>SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).</p>Fórmula:C50H62ClN11O6S2Pureza:98.07%Cor e Forma:SolidPeso molecular:1012.68EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Fórmula:C22H16N4OSCor e Forma:SolidPeso molecular:384.45SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Fórmula:C25H29F3N4O3Cor e Forma:SolidPeso molecular:490.52SNIPER(ABL)-033
CAS:<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Fórmula:C61H73F3N10O9S2Pureza:98%Cor e Forma:SolidPeso molecular:1211.42Trastuzumab envedotin
<p>Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.</p>Cor e Forma:Odour LiquidAnti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Cor e Forma:Odour LiquidYH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour LiquidMulti-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Pureza:98%Cor e Forma:Odour SolidDSPE-PEG1000-A7R
<p>DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Cor e Forma:Odour SolidAD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Fórmula:C22H20F3N7OPureza:99.05%Cor e Forma:SoildPeso molecular:455.44BTK inhibitor 19
CAS:<p>BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).</p>Fórmula:C25H24F3N7O3Cor e Forma:SolidPeso molecular:527.508PST3.1a
CAS:<p>PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).</p>Fórmula:C32H33O6PCor e Forma:SolidPeso molecular:544.57EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99BTK ligand-14
<p>BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.</p>Cor e Forma:Odour SolidALK protein ligand-1
CAS:<p>ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.</p>Fórmula:C24H29ClN6O3SCor e Forma:SolidPeso molecular:517.043PROTAC FGFR1 degrader-1
<p>PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.</p>Fórmula:C46H54N8O8Cor e Forma:SolidPeso molecular:846.97Hck-IN-2
<p>Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.</p>Fórmula:C36H35FN6O10Cor e Forma:SolidPeso molecular:730.696COVA208
<p>COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.</p>Cor e Forma:Odour LiquidPACAP-38 (31-38), human, mouse, rat TFA
<p>PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.</p>Fórmula:C49H84F3N17O13Pureza:98%Cor e Forma:SolidPeso molecular:1176.29EGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58HG-7-85-01
CAS:<p>HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.</p>Fórmula:C31H31F3N6O2SPureza:98.08%Cor e Forma:SolidPeso molecular:608.68IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidIMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Cor e Forma:Odour LiquidE7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Fórmula:C32H37N5O6Cor e Forma:SolidPeso molecular:587.67ABP-102
<p>ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.</p>Cor e Forma:Odour LiquidK882
<p>K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.</p>Fórmula:C18H16N2O2Cor e Forma:SolidPeso molecular:292.33
